Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00489541 · ClinicalTrials.gov registry record · Phase 3

TAXUS PERSEUS Small Vessel

A Phase 3 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
224
Enrollment target

NCT00489541 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 224 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00489541, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
224 participants
Enrollment target

Study Summary

The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to \< 2.75 mm diameter.

Interventions

  • DEVICE Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2007-07
Est. Completion 2013-10
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00489541

The ClinicalTrials.gov registry entry for NCT00489541 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation is the first listed.

NCT00489541 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00489541 about?

NCT00489541 is a clinical study titled "TAXUS PERSEUS Small Vessel". The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arter...

What is the current status of trial NCT00489541?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2007-07. Estimated completion is 2013-10.

What interventions are being tested in trial NCT00489541?

The interventions under investigation include: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation (DEVICE).

Who is sponsoring clinical trial NCT00489541?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.